XTAEGEFR
Market cap41mUSD
Dec 24, Last price
70.00ILS
1D
-0.28%
1Q
15.13%
IPO
-92.55%
Name
Geffen Residence & Renewal Ltd
Chart & Performance
P/E
—
P/S
107,525.92
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
139.97%
Rev. gr., 5y
%
Revenues
142k
+136.67%
Net income
-7m
L-65.59%
CFO
-61m
L+450.06%
Dividend
Sep 30, 20156.6337 ILS/sh
Profile
Geffen Residence & Renewal Ltd engages in the cultivation, production, storage, marketing, and sale of medical cannabis in Israel. It owns pharmacies, which sell cosmetics, convenience, and toiletries, as well as pharmacy and natural products, such as marketing prescription drugs, over-the-counter drugs, natural products, and vitamins and supplements. The company also offers plasters and bandages; and thermometer and humidifiers. The company was formerly known as Cannomed Medical Cannabis Industries Ltd. The company was incorporated in 1999 and is based in Tel Aviv-Yafo, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 142 136.67% | 60 -90.88% | 658 -96.33% | ||||||
Cost of revenue | 2,870 | 8,706 | 13,923 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (2,728) | (8,646) | (13,265) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (499) | 9,524 | 1,468 | ||||||
Tax Rate | |||||||||
NOPAT | (2,229) | (18,170) | (14,733) | ||||||
Net income | (6,910) -65.59% | (20,082) 49.58% | (13,426) 52.41% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 46,242 | 12,472 | |||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 3,164 | 5,730 | |||||||
Long-term debt | 45,276 | 213 | 11,549 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 14,220 | 1,721 | 5,730 | ||||||
| Cash flow | |||||||||
Cash from operating activities | (61,458) | (11,173) | (15,190) | ||||||
CAPEX | (292) | (56) | (2,737) | ||||||
Cash from investing activities | (292) | 3,553 | 10,734 | ||||||
Cash from financing activities | 91,150 | (2,279) | 11,023 | ||||||
FCF | (7,200) | 1,022 | (3,184) | ||||||
| Balance | |||||||||
Cash | 31,056 | 1,656 | 11,549 | ||||||
Long term investments | |||||||||
Excess cash | 31,049 | 1,653 | 11,516 | ||||||
Stockholders' equity | (15,887) | (11,412) | 9,340 | ||||||
Invested Capital | 118,953 | 19,006 | 25,632 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 215,636 | 99,386 | 88,042 | ||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (2,210) | (5,997) | (11,303) | ||||||
EV/EBITDA | |||||||||
Interest | 48 | 404 | 905 | ||||||
Interest/NOPBT | |||||||||